These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32573077)

  • 1. Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer.
    Zhao Q; Liu C; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):171-176. PubMed ID: 32573077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
    Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
    Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations.
    Sim JK; Choi J; Lee SY
    Korean J Intern Med; 2023 Nov; 38(6):787-796. PubMed ID: 37939663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.
    Zhao R; Guan X; Zhang P; Liu Y; Xu Y; Sun C; Qiu S; Zhu W; Yang Z; Wang X
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):175. PubMed ID: 38573518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
    J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.
    Ni J; Huang M; Zhang L; Wu N; Bai CX; Chen LA; Liang J; Liu Q; Wang J; Wu YL; Zhang FC; Zhang SY; Chen C; Chen J; Fang WT; Gao SG; Hu J; Jiang T; Li SQ; Li HC; Liao YD; Liu Y; Liu DR; Liu HX; Liu JY; Liu LX; Wang MZ; Wang CL; Yang F; Yang Y; Zhang LJ; Zhi XY; Zhong WZ; Guan YZ; Guo XX; He CX; Li SL; Li Y; Liang NX; Lu FL; Lv C; Lv W; Si XY; Tan FW; Wang HP; Wang JS; Yan S; Yang HX; Zhu HJ; Zhuang JL; Zhuo ML
    Thorac Cancer; 2021 May; 12(9):1469-1488. PubMed ID: 33787090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review.
    Mei T; Wang T; Lei C; Jiang D; Zhou Q
    Front Immunol; 2023; 14():1272450. PubMed ID: 38304254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.
    Tong BC; Gu L; Wang X; Wigle DA; Phillips JD; Harpole DH; Klapper JA; Sporn T; Ready NE; D'Amico TA
    J Thorac Cardiovasc Surg; 2022 Feb; 163(2):427-436. PubMed ID: 33985811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
    Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
    J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for early-stage non-small cell lung cancer: A system review.
    Gao J; Zhang C; Wei Z; Ye X
    J Cancer Res Ther; 2023 Aug; 19(4):849-865. PubMed ID: 37675709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resectable non-small cell lung cancer Adjuvant chemotherapy: slightly longer survival.
    Prescrire Int; 2016 Dec; 25(177):299-301. PubMed ID: 30758927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer.
    Watanabe SI; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Saji H; Yoshioka H; Zenke Y; Aoki T; Tsutani Y; Okada M;
    Jpn J Clin Oncol; 2017 Dec; 47(12):1112-1118. PubMed ID: 29136212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].
    Mignard X; Antoine M; Moro-Sibilot D; Dayen C; Mennecier B; Gervais R; Amour E; Milleron B; Morin F; Zalcman G; Wislez M
    Rev Mal Respir; 2018 Nov; 35(9):983-988. PubMed ID: 30243521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant and neoadjuvant therapy in non-small cell lung cancer.
    Belani CP
    Semin Oncol; 2005 Apr; 32(2 Suppl 2):S9-15. PubMed ID: 15818538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
    Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
    Savic M; Kontic M; Ercegovac M; Stojsic J; Bascarevic S; Moskovljevic D; Kostic M; Vesovic R; Popevic S; Laban M; Markovic J; Jovanovic D
    Thorac Cancer; 2017 Sep; 8(5):393-401. PubMed ID: 28671758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
    Nagasaka M; Gadgeel SM
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):63-70. PubMed ID: 29168933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
    Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.